Inicio・Lista de Acciones・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Abierto

SectorSanidad

9.54 2.14

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

9.3

Máximo

9.62

Métricas clave
By Trading Economics
Ingresos	-1.1B -722M
Ventas	-250M 156M
P/B Media del Sector	7.603 62.58
BPA	0.14
Margen de beneficios	-461.478
Empleados	435
EBITDA	-966M -700M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+132.38% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-22M 2.3B
Apertura anterior	7.4
Cierre anterior	9.54

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

280 / 340 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20 jul 2026, 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

132.38% repunte

Estimación a 12 Meses

Media 21.89 USD 132.38%

Máximo 32 USD

Mínimo 12 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

Comprar

Mantener

Vender

De acuerdo con 9 analistas que ofrecen calificaciones bursátiles a para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

280 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.